Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Studies from Novo Nordisk show an almost 25% reduction in adverse kidney outcomes for diabetes patients with CKD, and the company is trying to get Wegovys indications expanded to include CKD before years end
Tirzepatide reduces input more efficiently
For questions regarding your eligibility or benefits, or if you wish to discontinue your participation, call the Insulins Val you Savings Program at (833) 813-0190 (8:00 am-8:00 pm EST, Monday-Friday)
Eli Lilly and Company Today LLY Eli Lilly and Company $1,197.88 +1.85 (+0.15%) As of 07/27/2026 03:59 PM Eastern 52-Week Range $623.78 $1,249.45 Dividend Yield 0.58% P/E Ratio 42.55 Price Target $1,283.64 This massive size plays to Eli Lilly's advantage as it seeks to expand its GLP-1 agonist program globally
Esposito, The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes
Who qualifies for GLP-1 weight loss medication
